As the luminal A subtype has the best prognosis in BC, and the BRCA1 mRNA-low group had a larger proportion of luminal A patients, it is likely that this can explain the differences in overall survival [25], however the impact of subtype on differential patient outcomes across BRCA1 mRNA-low versus -high patients is unclear from this data. Here, BRCA1 is linked to breast cancer.